- Home
- IAE vs OPTN Comparison
IAE vs OPTN Comparison
Compare IAE & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAE
- OPTN
- Stock Information
- Founded
- IAE 2007
- OPTN 2010
- Country
- IAE United States
- OPTN United States
- Employees
- IAE N/A
- OPTN N/A
- Industry
- IAE Trusts Except Educational Religious and Charitable
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- IAE Finance
- OPTN Health Care
- Exchange
- IAE Nasdaq
- OPTN Nasdaq
- Market Cap
- IAE 68.1M
- OPTN 78.4M
- IPO Year
- IAE N/A
- OPTN 2017
- Fundamental
- Price
- IAE $6.11
- OPTN $6.38
- Analyst Decision
- IAE
- OPTN Strong Buy
- Analyst Count
- IAE 0
- OPTN 3
- Target Price
- IAE N/A
- OPTN $16.67
- AVG Volume (30 Days)
- IAE 46.3K
- OPTN 60.7K
- Earning Date
- IAE 01-01-0001
- OPTN 03-06-2025
- Dividend Yield
- IAE 10.21%
- OPTN N/A
- EPS Growth
- IAE N/A
- OPTN N/A
- EPS
- IAE N/A
- OPTN N/A
- Revenue
- IAE N/A
- OPTN $75,672,000.00
- Revenue This Year
- IAE N/A
- OPTN $13.42
- Revenue Next Year
- IAE N/A
- OPTN $38.54
- P/E Ratio
- IAE N/A
- OPTN N/A
- Revenue Growth
- IAE N/A
- OPTN 5.13
- 52 Week Low
- IAE $5.31
- OPTN $4.82
- 52 Week High
- IAE $6.45
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- IAE 49.07
- OPTN 49.78
- Support Level
- IAE $5.94
- OPTN $5.16
- Resistance Level
- IAE $6.13
- OPTN $6.97
- Average True Range (ATR)
- IAE 0.07
- OPTN 0.66
- MACD
- IAE 0.01
- OPTN 0.10
- Stochastic Oscillator
- IAE 62.96
- OPTN 71.08
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.